Results of a recently published long-term follow-up of the ASAP trial, which was conducted at universities and clinics across Germany, show that the genetic risk of disease, not remission status, determines overall survival of patients with high-risk acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Furthermore, there is no benefit of remission induction with standard salvage chemotherapy prior to allo-HSCT.
This article was originally published on MedicalXpress.com
